The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
The origin of MDMA (ecstasy) revisited: the true story reconstructed from the original documents*
Open accessAbstract
Background Little is known about the origin of methylenedioxymethamphetamine (MDMA, ecstasy). The most commonly repeated statement in the medical literature is that MDMA was synthesized by the German pharmaceutical company Merck in 1912 in order to develop an appetite suppressor. Aim To reconstruct the true story of the first known description of MDMA at Merck using the original documents. Methods A systematic analysis of the original documents in Merck’s historical archive in Darmstadt, Germany, was conducted (years 1900–60). Results There were no indications for plans to develop an appetite suppressant at Merck between 1900 and 1960. Although MDMA was, in fact, first synthesized at Merck in 1912, it was not tested pharmacologically because it was only an unimportant precursor in a new synthesis for haemostatic substances. The new pathway was patented in order to evade an existing patent by a local competitor. MDMA was called ‘Methylsafrylamin’ in 1912. In 1927 and 1959, the pharmacological effects of MDMA were studied at Merck, but not in humans. Discussion A systematic analysis of the original documents in the company’s archive revealed that uncritical copy‐paste procedures may have contributed to the famous myth that MDMA was patented as an appetite suppressor in 1912.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Pharmacology and Clinical Pharmacology of 3,4-Methylenedioxymethamphetamine (MDMA, “Ecstasy”)
Green, A. R., Mechan, A. O., Elliott, J. M., O’Shea, E., & Colado, M. I. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.3.3 · Cited by 1,272
Cited by
Mithoefer, M. C., Wagner, M. T., Mithoefer, A. T., Jerome, L., & Doblin, R. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110378371 · Cited by 674
“MDMA was patented in 1914 by the German chemical and pharmaceutical company Merck KGaA as an intermediate compound in the synthesis of other drugs (Benzenhoefer and Passie, 2006; Freudenmann et al., 2006).”
BackgroundBath salts and synthetic cathinones: An emerging designer drug phenomenon
German, C. L., Fleckenstein, A. E., & Hanson, G. R. (2014) · Life Sciences · doi:10.1016/j.lfs.2013.07.023 · Cited by 348
Molecular and Cellular Mechanisms of Ecstasy-Induced Neurotoxicity: An Overview
Capela, J. P., Carmo, H., Remião, F., Bastos, M. L., Meisel, A., & Carvalho, F. (2009) · Molecular Neurobiology · doi:10.1007/s12035-009-8064-1 · Cited by 290
Reviewing the Potential of Psychedelics for the Treatment of PTSD
Krediet, E., Bostoen, T., Breeksema, J., van Schagen, A., Passie, T., & Vermetten, E. (2020) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa018 · Cited by 260
Designer drugs: mechanism of action and adverse effects
Luethi, D., & Liechti, M. E. (2020) · Archives of Toxicology · doi:10.1007/s00204-020-02693-7 · Cited by 262
Metadata
- Authors
- Freudenmann, R. W., Öxler, F., & Bernschneider‐Reif, S.
- Venue
- Addiction
- Publisher
- Wiley
- Published
- 2006-08-08
- Volume
- 101
- Issue
- 9
- Pages
- 1241-1245
- ISSN
- 0965-2140 (ISSN-L)
- 1360-0443
- OpenAlex
- W2169132085
- Cited by
- 199
- References
- 1
- FWCI
- 6.17
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The origin of MDMA (ecstasy) revisited: the true story reconstructed from the original documents*. https://app.cochat.ai/papers/10.1111/j.1360-0443.2006.01511.x
- The paper
- Freudenmann, R. W., Öxler, F., & Bernschneider‐Reif, S. (2006). The origin of MDMA (ecstasy) revisited: the true story reconstructed from the original documents*. Addiction. https://doi.org/10.1111/j.1360-0443.2006.01511.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.